FDA’s Naloxone Product Approval Standards May See Changes
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.